In Silico Exploration of New Inhibitors of Protein Kinases Containing an N-Phenylbenzamide Linker: A Combination of Docking and Molecular Dynamics Modeling, Pharmacophore Modeling and Virtual Screening
Protein kinase inhibitors (PKIs) are widely used in the treatment of various human cancers. Still, their applications are limited by drug resistance (both intrinsic and acquired) and adverse toxicity. Beyond traditional design approaches, computational methods like pharmacophoric analysis, docking, and molecular dynamics have proven effective in PKI development. In this study, novel N-phenylbenzamide derivatives were designed as potential protein kinase inhibitors using the virtual combinatorial chemistry method guided by the pharmacophoric properties of approved PKIs. The antikinase activity of 25 studied structures was evaluated in silico using molecular docking and molecular dynamics protocols. Docking scores against 102 kinase receptors were obtained and benchmarked against reference ligands. MMPBSA binding energies were evaluated for the 36 most promising complexes in a series of 2 ns and 20 ns simulations. The results show that the designed structures are promising scaffolds for the development of new effective anticancer drugs.
References
[1]
Cicenas, J., Zalyte, E., Bairoch, A. and Gaudet, P. (2018) Kinases and Cancer. Cancers, 10, Article 63. https://doi.org/10.3390/cancers10030063
[2]
Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., et al. (2021) An Update of New Small-Molecule Anticancer Drugs Approved from 2015 to 2020. European Journal of Medicinal Chemistry, 220, Article 113473. https://doi.org/10.1016/j.ejmech.2021.113473
[3]
Riegel, K., Vijayarangakannan, P., Kechagioglou, P., Bogucka, K. and Rajalingam, K. (2022) Recent Advances in Targeting Protein Kinases and Pseudokinases in Cancer Biology. Frontiers in Cell and Developmental Biology, 10, Article 942500. https://doi.org/10.3389/fcell.2022.942500
[4]
Zhang, Z., Liu, X., Zhao, L., Zhou, Y., Shi, J., Chen, W., et al. (2022) A Review on the Treatment of Multiple Myeloma with Small Molecular Agents in the Past Five Years. European Journal of Medicinal Chemistry, 229, Article 114053. https://doi.org/10.1016/j.ejmech.2021.114053
[5]
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R. and Sounni, N.E. (2020) Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12, Article 731. https://doi.org/10.3390/cancers12030731
[6]
Lyseng-Williamson, K. and Jarvis, B. (2001) Imatinib. Drugs, 61, 1765-1774. https://doi.org/10.2165/00003495-200161120-00007
[7]
Roskoski, R. (2023) Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. Pharmacological Research, 187, Article 106552. https://doi.org/10.1016/j.phrs.2022.106552
[8]
Li, L., Liu, S., Wang, B., Liu, F., Xu, S., Li, P., et al. (2023) An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches. International Journal of Molecular Sciences, 24, Article 13953. https://doi.org/10.3390/ijms241813953
[9]
Cui, J.J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P., Pairish, M., et al. (2011) Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 54, 6342-6363. https://doi.org/10.1021/jm2007613
[10]
Yver, A. (2016) Osimertinib (AZD9291)—A Science-Driven, Collaborative Approach to Rapid Drug Design and Development. Annals of Oncology, 27, 1165-1170. https://doi.org/10.1093/annonc/mdw129
[11]
Kania, R.S. (2009) Structure‐Based Design and Characterization of Axitinib. In: Li, R.S. and Stafford, J.A., Eds., Kinase Inhibitor Drugs, Wiley, 167-201.
[12]
Zhao, H. and Caflisch, A. (2013) Discovery of ZAP70 Inhibitors by High-Throughput Docking into a Conformation of Its Kinase Domain Generated by Molecular Dynamics. Bioorganic & Medicinal Chemistry Letters, 23, 5721-5726. https://doi.org/10.1016/j.bmcl.2013.08.009
[13]
Wu, M., Han, J., Liu, Z., Zhang, Y., Huang, C., Li, J., et al. (2020) Identification of Novel CDK 9 Inhibitors Based on Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation. Life Sciences, 258, Article 118228. https://doi.org/10.1016/j.lfs.2020.118228
[14]
Al Shahrani, M., Gahtani, R.M., Abohassan, M., Alasmari, S. and Makkawi, M. (2023) Identification by Molecular Dynamic Simulation and in Vitro Validation of SISB-A1, N-[1-(4-Bromophenyl)-3-Methyl-1H-Pyrazol-5-Yl]-2-[(2-Oxo-4-Phenyl-2h-Chromen-7-Yl) Oxy], as an Inhibitor of the AblT315I Mutant Kinase to Combat Imatinib Resistance in Chronic Myeloid Leukemia. Medical Oncology, 40, Article No. 316. https://doi.org/10.1007/s12032-023-02182-8
[15]
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., et al. (2014) Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chemical Biology, 9, 1230-1241. https://doi.org/10.1021/cb500129t
[16]
Berman, H.M. (2000) The Protein Data Bank. Nucleic Acids Research, 28, 235-242. https://doi.org/10.1093/nar/28.1.235
[17]
NCI Chemical Identifier Resolver. http://cactus.nci.nih.gov/chemical/structure
[18]
Ravindranath, P.A., Forli, S., Goodsell, D.S., Olson, A.J. and Sanner, M.F. (2015) Autodockfr: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility. PLOS Computational Biology, 11, e1004586. https://doi.org/10.1371/journal.pcbi.1004586
[19]
Alhossary, A., Handoko, S.D., Mu, Y. and Kwoh, C. (2015) Fast, Accurate, and Reliable Molecular Docking with Quickvina 2. Bioinformatics, 31, 2214-2216. https://doi.org/10.1093/bioinformatics/btv082
Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., et al. (2015) GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX, 1, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
[22]
O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T. and Hutchison, G.R. (2011) Open Babel: An Open Chemical Toolbox. Journal of Cheminformatics, 3, Article No. 33. https://doi.org/10.1186/1758-2946-3-33
[23]
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., et al. (2004) UCSF Chimera—A Visualization System for Exploratory Research and Analysis. Journal of Computational Chemistry, 25, 1605-1612. https://doi.org/10.1002/jcc.20084
[24]
Lindorff‐Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J.L., Dror, R.O., et al. (2010) Improved Side‐chain Torsion Potentials for the Amber Ff99SB Protein Force Field. Proteins: Structure, Function, and Bioinformatics, 78, 1950-1958. https://doi.org/10.1002/prot.22711
[25]
Sousa da Silva, A.W. and Vranken, W.F. (2012) ACPYPE—AnteChamber PYthon Parser InterfacE. BMC Research Notes, 5, Article No. 367. https://doi.org/10.1186/1756-0500-5-367
[26]
Valdés-Tresanco, M.S., Valdés-Tresanco, M.E., Valiente, P.A. and Moreno, E. (2021) Gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with Gromacs. Journal of Chemical Theory and Computation, 17, 6281-6291. https://doi.org/10.1021/acs.jctc.1c00645
[27]
Kalinichenko, E., Faryna, A., Kondrateva, V., Vlasova, A., Shevchenko, V., Melnik, A., et al. (2019) Synthesis, Biological Activities and Docking Studies of Novel 4-(arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors. Molecules, 24, 3543. https://doi.org/10.3390/molecules24193543
[28]
Kalinichenko, E., Faryna, A., Bozhok, T. and Panibrat, A. (2021) Synthesis, in Vitro and in Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors. International Journal of Molecular Sciences, 22, 12738. https://doi.org/10.3390/ijms222312738
[29]
Vazquez, M.L., Kaila, N., Strohbach, J.W., et al. (2018) Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry, 61, 1130-1152.
[30]
Suebsuwong, C., Pinkas, D.M., Ray, S.S., Bufton, J.C., Dai, B., Bullock, A.N., et al. (2018) Activation Loop Targeting Strategy for Design of Receptor-Interacting Protein Kinase 2 (RIPK2) Inhibitors. Bioorganic & Medicinal Chemistry Letters, 28, 577-583. https://doi.org/10.1016/j.bmcl.2018.01.044
[31]
Smith, B.D., Kaufman, M.D., Wise, S.C., Ahn, Y.M., Caldwell, T.M., Leary, C.B., et al. (2021) Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular Cancer Therapeutics, 20, 2098-2109. https://doi.org/10.1158/1535-7163.mct-21-0361
[32]
Gajiwala, K.S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., et al. (2013) Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition. Structure, 21, 209-219. https://doi.org/10.1016/j.str.2012.11.014
[33]
Young, M.A., Shah, N.P., Chao, L.H., Seeliger, M., Milanov, Z.V., Biggs, W.H., et al. (2006) Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680. Cancer Research, 66, 1007-1014. https://doi.org/10.1158/0008-5472.can-05-2788
